linjc16/ctgov huggingface dataset:
N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement

Study Overview
=================
Brief Summary
-----------------
We aim to investigate the efficacy of N-acetylcysteine (NAC) to attenuate acute renal dysfunction in patients with rheumatic valvular heart disease undergoing single valve replacement.

Official Title
-----------------
N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement.

Conditions
-----------------
Cardiac Surgery for Rheumatic Valvular Heart Disease, Renal Dysfunction

Intervention / Treatment
-----------------
* Drug: N-acetylcysteine
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with rheumatic heart disease undergoing single valve replacement Exclusion Criteria: End stage renal disease (plasma creatinine concentration ≥ 300 µmol/L) Emergency cardiac surgery Planned off-pump cardiac surgery Chronic inflammatory disease on immunosuppression Chronic moderate to high dose corticosteroid therapy (≥ 10 mg/day prednisone or equivalent) Age ≤ 18 years.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: N-acetylcysteine<br>N-acetylcysteine bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs | Drug: N-acetylcysteine<br>* NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs<br>|
| Placebo Comparator: Glucose 5%<br>equivalent volume over the same period. | Drug: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absolute change in serum creatinine from baseline to peak level |  | within 5 days after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the relative change in serum creatinine. |  | the first five postoperative days |
Chlorhexidine Drying Time

Study Overview
=================
Brief Summary
-----------------
Before a patient gets a spinal/epidural, their lower back is cleaned with an antiseptic solution diluted in alcohol called ChloraPrep. ChloraPrep must completely dry before starting the anesthetic procedure. It is not known how much time is needed for the solution to completely dry. The investigators aim to determine this. As the ChloraPrep dries, the alcohol is converted into vapour. The investigators will be using a PPBRae 3000 device to detect small amounts of vapours in the air. As the ChloraPrep dries it gives off less and less vapour. The investigators will use this diminishing vapour concentration to determine when drying is complete.

Official Title
-----------------
The Minimum ChloraPrep Drying Time Before Neuraxial Anesthesia in Elective Cesarean Delivery Patients - Prospective Observational Study

Conditions
-----------------
Drying Time

Intervention / Treatment
-----------------
* Drug: Chlorhexidine gluconate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant At full term Due to have a cesarean section under spinal or epidural anesthesia 19 to 40 years of age Exclusion Criteria: Allergy to certain antiseptic solutions Not suitable for a spinal/epidural anesthetic Have a significant amount of hair on lower back

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study group<br>All study participants | Drug: Chlorhexidine gluconate<br>* antiseptic<br>* Other names: Chloraprep;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of Drying Time | Length of drying time from when Chloraprep solution is applied to skin to when skin is deemed dry. | At Chloraprep application | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
obstetric patients, chloraprep, chlorhexidine, drying time
Performance Study of the Invendo C20 Colonoscope System in Colorectal Cancer Screening

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate efficacy (i.e. reaching the cecum) and safety of the Invendo C20 Colonoscopy System

Official Title
-----------------
Clinical Study to Assess the Performance of the Invendo C20 Colonoscope System in Persons Undergoing Colorectal Cancer Screening at Average Risk for CRC

Conditions
-----------------
Colorectal Cancer Screening

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Screenees, i.e. asymptomatic persons willing to undergo screening colonoscopy, at average risk for colorectal cancer Age between 50-75 years Signed informed consent Exclusion Criteria: Family or personal history of colorectal neoplasia including familial adenomatous polyposis (FAP) or hereditary non-polyposis colorectal cancer Prior colonoscopy within preceding 10 years A suspected diagnosis of inflammatory bowel disease, bowel obstruction, acute diverticulitis, known severe diverticulosis or any known large bowel disease Clinically significant cardiovascular or pulmonary diseases Gastrointestinal-tract related symptoms, complaints or diseases suggesting performance of colonoscopy (no screening cases) Cancer or other life threatening diseases or significant chronic conditions Blood clotting disorders and /or anti-coagulant therapy including aspirin within the last 7 days Known pregnancy or positive screening pregnancy tests Previous abdominal surgery except for uncomplicated cholecystectomy, appendectomy or minor pelvic surgery (e.g. hernia repair, oophorectomy) Morbid obesity (BMI > 40) Clinically significant abnormal screening laboratory findings Clinically significant abnormal screening ECG findings Drug abuse or alcoholism Inability of the screenee to adequately communicate Screenees under custodial care Participation in a clinical study within the last 30 days

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| U.S. CRC screening population<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Intrauterine Autologous PRP Infusion Compared to HRT for Enhancing Endometrial Thickness in Patients Undergoing ICSI

Study Overview
=================
Brief Summary
-----------------
Successful embryo implantation needs an optimum embryonic development with a receptive endometrium. Endometrial thickness is an independant factor for endometrial receiptivity. The aim of that trial is to assess the benefecial effect of platelt rich plasma in copmarison with standard hormonal therapy.

Detailed Description
-----------------
This is a single blinded randomized trial comparing the effect of of platlet rich plasma versus hormonal therapy on endometrial thickness and consequently endometrial receptivity. The primary endpoint of this trial is clinical pregnancy rate.

Official Title
-----------------
Intrauterine Autologous Platelet -Enriched Plasma Infusion Compared to Hormonal Replacement Therapy for Enhancing Endometrial Thickness in Patients Undergoing ICSI

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Biological: platlet rich plasma


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing ICSI endometrial thickness less than 7 mm on early follicular phase Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Platlet rich plasma<br>For those with endometrial thickness less than 7 mm intrauterine injection of platlet rich plasma (PRP) for enhancing endometrial thickness and receptivity | Biological: platlet rich plasma<br>* Platelet-rich plasma (PRP) is prepared from fresh whole blood which is collected from a peripheral vein, stored in acid citrate dextrose solution A (ACD-A) anticoagulant and processed to increase platelets by separating various components of blood<br>|
| No Intervention: Hormone replacement therapy<br>Oral intake of estradiol valerate for those with endometrial thickness less than 7 mm will improve endometrial receptivity | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endometrial thickness in mm | using transvaginal ultrasound to measure endometrial thickness in mm | 72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical pregnancy rate | using transvaginal ultrasound to detect fetal cardiac activity | 4 weeks after embryo transfer |
Comparison of Pantomiming and Easy Onset Treatment

Study Overview
=================
Brief Summary
-----------------
This research will give in-depth understanding of pantomiming and easy onset method as an intervention of stuttering and especially blocking. And by comparing both methods, It will also determine that which method is more effective. This research will also improve the overall awareness regarding stuttering

Detailed Description
-----------------
Research participants will be divided into two groups through randomization, Group A & Group B. Base line assessment will be conducted. Intervention will be provided (thrice a week on alternative days).post assessment will be taken and data will be analyzed through SPSS.

Official Title
-----------------
Comparison of Pantomiming and Easy Onset Treatment on Blocking in Stammering

Conditions
-----------------
Stammering

Intervention / Treatment
-----------------
* Other: Pantomiming
* Other: Easy onset


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants falling in this category would be added into the study. School aged children and adolescents ages between 6 to 18 years(both genders) who stutter with blocking symptoms Participant who will be at moderate level of stammering will be included Exclusion Criteria: Participant failing to fall in this category would be excluded of the study. Participants with any other medical condition will be excluded

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: RCT
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pantomimng<br>In experimental group pantomiming treatment will be administered | Other: Pantomiming<br>* Pantomiming with fluency shaping techniques<br>|
| Active Comparator: Easy onset<br>In active comparator group easy onset method will be administered | Other: Easy onset<br>* Easy onset method with breathing exercises<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The real time analysis | Changes from base line The Real time analysis will use. It will use to assessed the changes in frequency ,duration types and severity of disfluencies in spontaneous speech.The total number of dysfluencies will be divided by the total number of syllables then multiply answer by 100 .Results between 2% showed normal range,8-15% will consider Moderate level, 12% will consider as severe level | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pantomiming, Easy onset method, Blocking
Applying Neuromodulation to Accelerate Training Effects

Study Overview
=================
Brief Summary
-----------------
This study seeks to understand at how noninvasive electrical brain stimulation might change how people perform on on tasks requiring concentration and thinking skills.

Detailed Description
-----------------
This study uses noninvasive electrical stimulation delivered through seeks to understand at how noninvasive electrical brain stimulation might change how people perform on on tasks requiring concentration and thinking skills.

Official Title
-----------------
Applying Neuromodulation to Accelerate Training Effects

Conditions
-----------------
Cognition

Intervention / Treatment
-----------------
* Device: Transcranial Electrical Stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People may participate in the experiment if they have normal or corrected vision, are in good health, and are at least 18 years old. Exclusion Criteria: People will be screened and excluded from participation if they are currently ill or if they report any history of seizures, if they lack the capacity to consent or appear to lack capacity to consent, if they have participated in previous thinking skills training or brain stimulation, or if they are currently taking certain substances/medications that might change thinking skills.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Stimulation<br>subject receives minimal transcranial electrical stimulation | Device: Transcranial Electrical Stimulation<br>* Transcranial Electrical Stimulation<br>* Other names: XCITE 100 (Pulvinar Neuro);|
| Left Side Stimulation<br>transcranial electrical stimulation on the left side of the head. | Device: Transcranial Electrical Stimulation<br>* Transcranial Electrical Stimulation<br>* Other names: XCITE 100 (Pulvinar Neuro);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Working memory | Working Memory | Baseline through 2 months |
Assessment of Vitamin B12 Bioavailability From Egg

Study Overview
=================
Brief Summary
-----------------
The hypothesis of this study is that chicken eggs can be enriched in vivo with 14C-B12 and fed to healthy human subjects to determine B12 bioavailability from eggs. The goal of this research is to enrich eggs in vivo with radioactively labeled vitamin B12 to a level that allows us to feed the enriched eggs to humans and determine how much of the vitamin B12 is digested and absorbed into the body. This will tell us if eggs are a good dietary source of vitamin B12. Importantly, sensitive technology available at the Lawrence Livermore National Laboratories allows us to measure very low amounts of radioactive vitamin B12. This allows us to do this experiment with a level of radioactive B12 that is not harmful to animals or humans. The results of the investigators first experiment indicate that the investigators can inject radioactively labeled vitamin B12 into a laying hen and detect the radioactive vitamin B12 in the eggs at a level sufficient for feeding to humans in a bioavailability study.

Official Title
-----------------
Assessment of Vitamin B12 Bioavailability From Egg

Conditions
-----------------
Bioavailability of Vitamin B12 From Chicken Eggs

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: normal healthy subjects, adequate B12 status and absorptive capacity and the availability to complete the protocol. Exclusion Criteria: any chronic health disorder, anemia of any kind, renal insufficiency, and pregnancy or lactation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fecal enrichment of 14C |  | Over the course of 8 days after dosing with 14C labeled egg | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vitamin B12, egg, 14C, fecal excretion
Comparison of Photorefractive Keratectomy (PRK) and Sub-Bowman's Keratomileusis (SBK)

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to compare clinical outcomes from PRK and SBK using FDA-approved laser technology in the same patient

Detailed Description
-----------------
Patients undergoing bilateral laser refractive surgery on the same day will be randomly assigned to have one eye treated with PRK and the fellow eye treated with SBK.

Official Title
-----------------
Comparison of Photorefractive Keratectomy (PRK) and Sub-Bowman's Keratomileusis (SBK): Assessment of Visual Function and Patient Satisfaction

Conditions
-----------------
Myopia

Intervention / Treatment
-----------------
* Procedure: PRK
* Procedure: SBK


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients deemed to be suitable candidates for bilateral LASIK surgery Exclusion Criteria: Patients who desire monovision correction rather than bilateral distance correction

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>PRK | Procedure: PRK<br>* Laser refractive surgery<br>|
| Active Comparator: 2<br>SBK | Procedure: SBK<br>* Laser refractive surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Manifest refraction |  | 6 months | 
| Wavefront aberration value |  | 6 months |
Evaluating Validity of Clinical Criteria for Requesting Chest X-Rays in Trauma Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to identify the clinical criteria for requesting a chest x-ray in a patient with blunt trauma and its findings such as clinical signs with a high sensitivity could be used in a larger study to codify the final criteria.

Detailed Description
-----------------
At present, a Chest x-ray is obtained from all trauma patients having suspicion to chest trauma. The indications for such radiographs are not well defined. This results in a large number of unnecessary chest radiographs being obtained. Our goal was to identify the clinical criteria for requesting a chest x-ray in a patient with blunt trauma and its findings such as clinical signs with a high sensitivity could be used in a larger study to codify the final criteria.

Official Title
-----------------
Study of Accuracy of Clinical Examination for Chest Trauma

Conditions
-----------------
Chest Trauma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Every patient with blunt trauma to chest Exclusion Criteria: nothing
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chest trauma<br>chest x-ray applied for patients with chest trauma and the manifestations compared with clinical examination | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| chest pain | for Assessing the accuaracy of this outcome we evaluated this one with chest x-ray manifestation | 5 min after admision time | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| tachypnea | for Assessing the accuaracy of this outcome we evaluated this one with chest x-ray manifestation | 5 min after admision time | 
| abrasion | for Assessing the accuaracy of this outcome we evaluated this one with chest x-ray manifestation | 5 min after admision time | 
| crepitation | for Assessing the accuaracy of this outcome we evaluated this one with chest x-ray manifestation | 5 min after admision time | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CXray